Soluble ctla4 mutant molecules and uses thereof

摘要

The present invention relates to soluble CTLA4 mutant molecules having a higher avidity for CD86 than wildtype CTLA4, pharmaceutical compositions comprising said soluble CTLA4 mutant molecules, immunosuppressive combinations comprising said soluble CTLA4 mutant molecules and at least one further immunosuppressant, and the use of said soluble CTLA4 mutant molecules for immune suppression, for treating immune system diseases and, in combination with a ligand reactive with IL-4, for inhibiting graft versus host disease (GVHD). Also, the invention relates to in vitro methods for regulating functional CTLA4 and CD28 positve T cell interactions with CD80 and/or CD86 positive cells. The present invention also relates to nucleic acid molecules encoding the amino acid sequence corresponding to said CTLA4 mutant molecules, plasmids comprising said nucleic acid molecules, and host vector systems comprising said plasmids. Further, the present invention relates to methods for producing a protein comprising growing said host vector system, and proteins obtainable by said methods.